Two Long-acting GLP-1 Agonists Have Differing Efficacy, Tolerability Two Long-acting GLP-1 Agonists Have Differing Efficacy, Tolerability

Results of an open-label study provide more evidence of variability in efficacy and tolerability of agents in the long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist class of diabetes medicines.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news